About: Diabetes and COVID-19: evidence, current status and unanswered research questions

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Diabetes and COVID-19: evidence, current status and unanswered research questions Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Diabetes and COVID-19: evidence, current status and unanswered research questions
Creator	Gupta, Ritesh Misra, Anoop Hussain, •
Source	Medline; PMC
abstract	Patients with diabetes who get coronavirus disease 2019 (COVID-19) are at risk of a severe disease course and mortality. Several factors especially the impaired immune response, heightened inflammatory response and hypercoagulable state contribute to the increased disease severity. However, there are many contentious issues about which the evidence is rather limited. There are some theoretical concerns about the effects of different anti-hyperglycaemic drugs. Similarly, despite the recognition of angiotensin converting enzyme 2 (ACE2) as the receptor for severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), and the role of ACE2 in lung injury; there are conflicting results with the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) in these patients. Management of patients with diabetes in times of restrictions on mobility poses some challenges and novel approaches like telemedicine can be useful. There is a need to further study the natural course of COVID-19 in patients with diabetes and to understand the individual, regional and ethnic variations in disease prevalence and course.
has issue date	2020-05-13(xsd:dateTime)
bibo:doi	10.1038/s41430-020-0652-1
bibo:pmid	32410783
has license	no-cc
sha1sum (hex)	7efe3f925876eb0518ed29586e7b03fed45fc08f
schema:url	https://doi.org/10.1038/s41430-020-0652-1
resource representing a document's title	Diabetes and COVID-19: evidence, current status and unanswered research questions
has PubMed Central identifier	PMC7220586
has PubMed identifier	32410783
schema:publication	Eur J Clin Nutr
resource representing a document's body	covid:7efe3f925876eb0518ed29586e7b03fed45fc08f#body_text
is schema:about of	named entity 'angiotensin' named entity 'However' named entity 'metabolomics' named entity 'RECEPTOR' named entity 'MANAGEMENT' named entity 'TIMES' named entity 'ROLE' named entity 'APPROACHES' named entity 'VARIATIONS' named entity 'prevalence' named entity 'disease' named entity 'enzyme' named entity 'drugs' named entity 'severe' named entity 'ARB' named entity 'diabetes' named entity 'There' named entity 'lung' named entity 'immune response' named entity 'COVID' named entity 'ARB' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'diabetes' named entity 'Metabolism' named entity 'Diabetes' named entity 'metabolomics' named entity 'Corticosteroids' named entity 'TNF-alfa' named entity 'hypertension' named entity 'gastrointestinal' named entity 'thiazolidinediones' named entity 'sulfonylureas' named entity 'agonists' named entity 'natural killer cell' named entity 'metalloprotease' named entity 'virulence' named entity 'ACE inhibition' named entity 'angiotensin 2' named entity 'ACE inhibitors' named entity 'ACE2' named entity 'ACE2' named entity 'infection' named entity 'COVID' named entity 'Sulfonylureas' named entity 'angiotensin' named entity 'India' named entity 'ARB' named entity 'DPP4' named entity 'dehydration' named entity 'blood glucose monitoring' named entity 'Metformin' named entity 'ketoacidosis' named entity 'Chloroquine' named entity 'disintegrin' named entity 'American Heart Association' named entity 'glycaemic' named entity 'COVID-19' named entity 'blood glucose' named entity 'dipeptidyl peptidase 4' named entity 'hyperglycaemia' named entity 'diabetes' named entity 'diabetes' named entity 'higher risk' named entity 'insulin' named entity 'obesity' named entity 'COVID' named entity 'obesity' named entity 'secretion' named entity 'DPP4' named entity 'diabetes' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'ACE2' named entity 'High-risk groups' named entity 'false negative' named entity 'ARDS' named entity 'ARBs' named entity 'self-care' named entity 'COVID-19' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software